Imperial College London
Portrait Picture

DrPervizAsaria

Faculty of Medicine, School of Public Health

Honorary Clinical Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7594 2547p.asaria

 
 
//

Location

 

524Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Fontana:2014:10.1161/CIRCULATIONAHA.113.007595,
author = {Fontana, M and Asaria, P and Moraldo, M and Finegold, J and Hassanally, K and Manisty, CH and Francis, DP},
doi = {10.1161/CIRCULATIONAHA.113.007595},
journal = {Circulation},
pages = {2539--2546},
title = {Patient-accessible tool for shared decision making in cardiovascular primary prevention balancing longevity benefits against medication disutility},
url = {http://dx.doi.org/10.1161/CIRCULATIONAHA.113.007595},
volume = {129},
year = {2014}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background—Primary prevention guidelines focus on risk, often assuming negligible aversion to medication, yet most patients discontinue primary prevention statins within 3 years. We quantify real-world distribution of medication disutility and separately calculate the average utilities for a range of risk strata.Method and Results—We randomly sampled 360 members of the general public in London. Medication aversion was quantified as the gain in lifespan required by each individual to offset the inconvenience (disutility) of taking an idealized daily preventative tablet. In parallel, we constructed tables of expected gain in lifespan (utility) from initiating statin therapy for each age group, sex, and cardiovascular risk profile in the population. This allowed comparison of the widths of the distributions of medication disutility and of group-average expectation of longevity gain. Observed medication disutility ranged from 1 day to >10 years of life being required by subjects (median, 6 months; interquartile range, 1–36 months) to make daily preventative therapy worthwhile. Average expected longevity benefit from statins at ages ≥50 years ranges from 3.6 months (low-risk women) to 24.3 months (high-risk men).Conclusion—We can no longer assume that medication disutility is almost zero. Over one-quarter of subjects had disutility exceeding the group-average longevity gain from statins expected even for the highest-risk (ie, highest-gain) group. Future primary prevention studies might explore medication disutility in larger populations. Patients may differ more in disutility than in prospectively definable utility (which provides only group-average estimates). Consultations could be enriched by assessing disutility and exploring its reasons.
AU  - Fontana,M
AU  - Asaria,P
AU  - Moraldo,M
AU  - Finegold,J
AU  - Hassanally,K
AU  - Manisty,CH
AU  - Francis,DP
DO  - 10.1161/CIRCULATIONAHA.113.007595
EP  - 2546
PY  - 2014///
SN  - 0009-7322
SP  - 2539
TI  - Patient-accessible tool for shared decision making in cardiovascular primary prevention balancing longevity benefits against medication disutility
T2  - Circulation
UR  - http://dx.doi.org/10.1161/CIRCULATIONAHA.113.007595
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000337705900012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.113.007595
VL  - 129
ER  -
Download